Abstract
Programmed cell death (apoptosis) seems to be the principal mechanism whereby anti-oncogenic therapies such as chemotherapy and radiation effect their responses. Resistance to apoptosis, therefore, is probably a principal mechanism whereby tumors are able to overcome these cancer therapies. The transcription factor NF-κB is activated by chemotherapy and by irradiation in some cancer cell lines. Furthermore, inhibition of NF-κB in vitro leads to enhanced apoptosis in response to a variety of different stimuli. We show here that inhibition of NF-κB through the adenoviral delivery of a modified form of IκBα, the inhibitor of NF-κB, sensitizes chemoresistant tumors to the apoptotic potential of TNFκ and of the chemotherapeutic compound CPT-11, resulting in tumor regression. These results demonstrate that the activation of NF-κB in response to chemotherapy is a principal mechanism of inducible tumor chemoresistance, and establish the inhibition of NF-κB as a new approach to adjuvant therapy in cancer treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fisher, D.E. Apoptosis in cancer therapy: crossing the threshold. Cell 73, 539–542 (1994).
Baldini, N. Multidrug resistance–a multiplex phenomenon. Nature Med. 3, 378–380 (1997).
Friesen, C., Herr, I., Krammer, P. & Debatin, K.-M. Involement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 2, 574– 577 (1996).
Fulda, S., Susin, S., Kroemer, G. & Debatin, K.-M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 58, 4453–4460 (1998).
Held, D.K. Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis 2, 265–282 (1997).
Tewari, M. & Dixit, V. Recent advances in TNF and CD40 signaling. Curr. Opin. Gen. Dev. 6, 39– 44 (1996).
Datta, R. et al. Activation of the CPP32 protease in apoptotis induced by 1-β-D-arabinofuranosylcyotosine and other DNA damaging agents. Blood 88, 1936–1943 (1996).
Wang, C.-Y., Mayo, M.W. & Baldwin, A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274, 784–787 (1996).
Beg, A.A. & Baltimore, D. An essential role for NF-κB in preventing TNFα-induced cell death. Science 274, 782–784 (1996).
Van Antwerp, D., Martin, S.J., Kafri, T., Green, D.R. & Verma, I. M. Suppression of TNFα-induced apoptosis by NF-κB. Science 274, 787–789 (1996).
Liu, Z.G., Hsu, H., Goeddel, D.V. & Karin, M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87 , 565–576 (1996).
Arsura, M., Wu, M. & Sonenshein, G.E. TGFβ1 inhibits NF-κB/Rel activity inducing apoptosis of B-cells: transcriptional activation of IκBα. Immunity 5, 31–40 ( 1996).
Baldwin, A.S. The NF-κB and IκB proteins: new discoveries and insights. Ann. Rev. Immunol. 14, 649–681 (1996).
Ghosh, S., May, M.J. & Kopp, E.B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Ann. Rev. Immunol. 16 , 225–260 (1998).
Spriggs, D.R. & Yates, D.R. in Tumor necrosis factors: The Molecules and their Emerging Roles in Medicine (ed. Beutler, B) 383– 407 (Raven, New York, 1992).
Eggermont, A., Manusama, E. & ten Hagen, T.L.M. Regional application of TNFα in the treatment of cancer: a preclinical-clinical interactive program. J. Inflamm. 47, 104 –113 (1996).
Mauceri, H.J. et al. TNFα gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 56, 4311–4314 (1996).
Ruegg, C. et al. Evidence of the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFNγ. Nature Med. 4, 408-414 (1998).
Brockman, J.A. et al. Coupling of a signal response domain in IκBα to multiple pathways for NF-κB activation. Mol. Cell. Biol. 15, 2809–2818 (1995).
Iimuro, Y. et al. NF-κB prevents apoptosis and liver dysfunction during liver regeneration. J. Clin. Invest. 101, 802–811 (1998).
Takimoto, C.H. & Arbuck, S.G. in Cancer Chemotherapy and Biotherapy (eds. B. Chabner, B. & Longo, D.) 463– 484 (Lippincott-Raven, New York, 1996).
Piret, B. & Piette, J. Topoisomerase poisons activate the transcription factor NF-κB in ACH2 and CEM cells. Nucl. Acids Res. 24, 4242–4248 ( 1996).
Slater, A., Kimland, M., Jiang, S.A. & Orrenius, S. Constitutive nuclear NF-κB/Rel DNA-binding activity of rat thymocytes is increased by stimuli that promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate. Biochem. J. 312, 833–838 (1995).
Das, K.C. & White, C.W. Activation of NF-κB by antineoplastic agents: role of protein kinase C. J. Biol. Chem. 272 , 14914–14920 (1997).
Oshita, F. et al. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J. Clin. Oncol. 15, 304–309 (1997).
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H. & Sato, K. Intracellular role of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51, 4187–4191 (1991).
Hickman, J.A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 11, 121–139 (1992).
Kerr, J.F. et al. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013–2026 (1994).
Merlino, G. Regulatory imbalances in cell proliferation and cell death during oncogenesis in transgenic mice. Sem. Cancer Biol. 5, 13–20 (1994).
Graeber, T.G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379, 88 –91 (1996).
Chmura, S.J. et al. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and spinghomyelinase activation increases tumor killing by ionizing radiation. Cancer Res. 57, 4340 –4347 (1997).
Mauceri, H.J. et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 394, 287– 291 (1998).
Heise, C. et al. ONYX-015, an E1B-gene attenuated adenovirus, causes tumor-specific cytolysis and antitumor efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3, 639– 645 (1997).
Holtmann, H., Hahn, T. & Wallach, D. Interrelated effects of TNF and IL-1 on cell viability. Immunobiology 177, 7–22 (1988).
Wang, C.-Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V. & Baldwin, A.S. NF-κB antiapoptosis: induction of TRAF1, TRAF2, c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680–1683 ( 1998).
Roy, N., Devereaux, Q.L., Takahashi, R., Salvesen, G. & Reed, J.C. EMBO J. 16, 6914 (1997).
Mayo, M. et al. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278, 1812–1815 (1997).
Arai, H., Gordon, D., Nabel, E.G. & Nabel, G.J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Nat. Acad. Sci. USA 94, 13862–13867 (1997).
Weichselbaum, R. and Kufe, D. Gene therapy of cancer. Lancet 349 (suppl.), 10sII– 12sII (1997).
Roth, J.A. et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2, 985–991 (1996).
Lowe, S. Progress of the smart bomb cancer virus. Nature Med. 3, 606–608 (1997).
Conner, E.M. et al. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J. Pharm. Exp. Ther. 282, 1615–1622 (1997).
Cusack, J.C. et al. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther. 3, 245–149 ( 1996).
Acknowledgements
The authors thank Y. Lin for assistance with statistical analysis. We also acknowledge J. Roth for Ad.CMV3. This work has been funded by the UNC Lineberger Comprehensive Cancer Center (J.C.C.), by the American Cancer Society Clinical Oncology Career Development Award 96-21 (J.C.C.) and by research grants CA73756, CA75080 and AI35098 (to A.S.B.) and CA75528 (to J.C.C.)from the NIH and by a Leukemia Society of America grant (to A.S.B.). Support for C.-Y.W. was provided by NIH grant DE12823. Additional support for this project was provided by the UNC SPORE program in breast cancer (NCI grant CA58223).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wang, CY., Cusack, J., Liu, R. et al. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5, 412–417 (1999). https://doi.org/10.1038/7410
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/7410
This article is cited by
-
MCPIP1 Suppresses the NF-κB Signaling Pathway Through Negative Regulation of K63-Linked Ubiquitylation of TRAF6 in Colorectal Cancer
Cancer Gene Therapy (2023)
-
Mitochondrial dysfunction, UPRmt signaling, and targeted therapy in metastasis tumor
Cell & Bioscience (2021)
-
UBE2S activates NF-κB signaling by binding with IκBα and promotes metastasis of lung adenocarcinoma cells
Cellular Oncology (2021)
-
Inhibition of IKKβ/NF-κB signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma
Cell Death Discovery (2020)
-
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer
Journal of Experimental & Clinical Cancer Research (2019)